<DOC>
	<DOCNO>NCT02234739</DOCNO>
	<brief_summary>voriconazole recommend first-line therapy invasive pulmonary aspergillosis , however efficacy safety voriconazole treat invasive pulmonary aspergillosis secondary COPD clear . This study aim investigate effectiveness tolerability intravenous voriconazole treatment invasive pulmonary aspergillosis Chinese patient COPD , monitoring change clinical symptom , eradication aspergillus , improvement chest image well record possible adverse reaction follow 2-week intravenous instillation voriconazole .</brief_summary>
	<brief_title>Voriconazole IPA Chinese Patients With COPD</brief_title>
	<detailed_description>This multiple-center open-label clinical trial study efficacy safety voriconazole treat invasive pulmonary aspergillosis secondary COPD Chinese patients.The primary endpoint treatment success rate define improvement symptom relate invasive pulmonary asperillosis , secondary endpoint include mortality , eradication sputum asperillus profile adverse reaction follow intravenous instillation voriconazole .</detailed_description>
	<mesh_term>Aspergillosis</mesh_term>
	<mesh_term>Invasive Pulmonary Aspergillosis</mesh_term>
	<mesh_term>Pulmonary Aspergillosis</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<criteria>Cases invasive pulmonary aspergillosis secondary COPD Use voriconazole itraconazole amphotericin B caspofungin micafungin within 4 week prior enrollment Known allergy voriconazole Severe impairment live kidney function Septic shock Unwilling sign inform consent</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>voriconazole</keyword>
	<keyword>COPD</keyword>
	<keyword>invasive pulmonary aspergillosis</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
</DOC>